Oramed Pharmaceuticals Inc.: Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

ORMD-0801 positioned to potentially be the first FDA approved oral insulin for the treatment of diabetes Completed enrollment of 710 patients for the Phase 3 ORA-D-013-1 study Top

Related Keywords

United States ,Israel ,Nadav Kidron ,Eric Goldstein ,Zach Herschfus ,Exchange Commission ,Prnewswire Oramed Pharmaceuticals Inc ,Drug Administration ,Oramed Pharmaceuticals ,Oramed Pharmaceuticals Nasdaq ,Nasdaq ,Protein Oral Delivery ,Oramed ,Pharmaceuticals ,Ompletes ,Patient ,Enrollment ,Pivotal ,Hase ,Mural ,Insulin ,Study ,